Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Subscribe To Our Newsletter & Stay Updated